Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 7/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.37 |
| ▸ | PPARD | Q03181 | 8/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 5/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3966439 | 0.84 | PPARD (0.48) | PPARAPPARDFFAR1PPARG | |
| SCHEMBL3961926 | 0.80 | HTR2A (0.52) | HSD17B1PPARAPPARDFFAR1 | |
| SCHEMBL3965573 | 0.75 | POLB (0.41) | HSD17B1CYP11B1CYP11B2PPARD | |
| SCHEMBL3964420 | 0.74 | HSD17B1 (0.44) | HSD17B1PPARACYP11B1CYP11B2PPARD | |
| SCHEMBL3964872 | 0.73 | THRA (0.38) | HSD17B1PPARAPPARD | |
| SCHEMBL6816306 | 0.73 | PPARA (0.43) | PPARACYP11B1CYP11B2PPARDPPARG | |
| SCHEMBL21538693 | 0.72 | NQO2 (0.56) | HSD17B1PPARAPPARD | |
| SCHEMBL6816310 | 0.71 | PPARA (0.43) | PPARACYP11B1CYP11B2PPARDPPARG | |
| SCHEMBL9017256 | 0.71 | ACHE (0.34) | CYP11B1CYP11B2FFAR1 | |
| SCHEMBL6816298 | 0.71 | PPARA (0.37) | HSD17B1PPARACYP11B1CYP11B2PPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2006271-A9 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2009-07-29 | — | — | EP | disclosed |
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-02-26 | — | — | US | disclosed |
| EP-2006271-A2 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2008-12-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | LTB4R2, LTC4S, LTB4R | HSD17B1 452/4885PPARA 120/4885CYP11B1 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.